GLP-1s
PulseAugur coverage of GLP-1s — every cluster mentioning GLP-1s across labs, papers, and developer communities, ranked by signal.
5 day(s) with sentiment data
-
Eli Lilly CEO Bets Billions on New Drugs After GLP-1 Success
Eli Lilly's CEO, Dave Ricks, is investing heavily to replicate the success of the company's GLP-1 drugs, which propelled Eli Lilly to a $1 trillion valuation. Despite the significant revenue generated by these drugs, wh…
-
Ozempic and GLP-1s Show Potential for Slowing Molecular Aging
Recent findings from Novo Nordisk and Eli Lilly suggest that GLP-1 medications, commonly used for diabetes and weight loss, may also have a beneficial effect on slowing the aging process at a molecular level. This poten…
-
Mark Cuban: Healthcare Costs, Not AI, Are the Real Job Killer
Mark Cuban argues that escalating healthcare costs, rather than artificial intelligence, pose the most significant threat to employment. He points to rising healthcare expenditures as a primary driver for companies redu…
-
Weight-loss drugs may slow biological aging, studies suggest
Weight-loss drugs like GLP-1s from Eli Lilly and Novo Nordisk are showing potential to slow biological aging, according to molecular aging clocks. These drugs, which stimulate appetite suppression, have demonstrated a r…
-
Hershey CEO Discusses AI Integration and Brand Relevance Amidst Evolving Consumer Trends
Hershey CEO Kirk Tanner discussed the company's approach to integrating AI into its operations and marketing strategies. He highlighted the potential impact of GLP-1 drugs on consumer behavior and the company's efforts …
-
RonanRx launches personalized peptide and GLP-1 platform
RonanRx, a Y Combinator S26 startup, is developing a vertically integrated pharmaceutical company focused on personalized peptides and GLP-1 medications. The company aims to streamline the entire process from prescripti…
-
Bank of America maintains GLP-1 coverage amid employer trend reversal
Bank of America is distinguishing itself by continuing to offer comprehensive employer-sponsored coverage for GLP-1 medications used to treat obesity. This stance contrasts with a broader industry trend where many compa…
-
Medicaid weight loss drug access model sees minimal state participation
A voluntary Medicaid demonstration project aimed at expanding access to weight loss drugs, known as the BALANCE model, has garnered very little interest from states, with Indiana being the only confirmed participant. Th…
-
AI and modern conveniences blamed for 'joyless decadence'
Hosts Kai Wright and Carter Sherman explore the paradox of modern life, where technological advancements and conveniences paradoxically lead to feelings of emptiness and a lack of joy. They discuss with academics Michèl…
-
Medical startup sells $345 nuclear disaster kit, experts call it overpriced
A telehealth startup named Amble Health is selling a $345 "Oh Sh*t Kit" containing prescription medications like iodine tablets and anti-nausea drugs, marketed as a preparedness measure for nuclear disasters. While the …
-
Telehealth network scammed customers out of $5M for GLP-1s
Customers have reported being scammed by a telehealth network that sells compounded GLP-1 medications. This network was previously ordered to pay $5 million to clients as part of a settlement with the US government. The…
-
Weight loss drug coverage uncertain despite insurer formulary listings
Despite Eli Lilly's announcement that its obesity medications will be listed on the formularies of major pharmacy benefit managers, actual coverage remains uncertain. Many health insurers and plan sponsors are reluctant…
-
SCMP Lifestyle: Consort Wan's tale and GLP-1s highlighted
This cluster focuses on lifestyle highlights from SCMP's recent reporting, including a historical piece about Consort Wan and her relationship with Emperor Chenghua. It also touches upon the benefits and potential downs…